Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders

Running, not enrolling · Phase 4

Conditions studied: Peyronie's Disease

In brief

Compare key clinical outcomes between controls and men treated with a novel CCH administration protocol among men previously unresponsive to CCH administration.

Key facts

Study ID

NCT05108558

Run by

Charitable Union for the Research and Education of Peyronie's Disease

People needed

40

Starts

2021-09-20

Expected to finish

2028-09-20

Last updated by the study team

2025-02-13

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Men with Peyronie's Disease
• >18 years old
• Curvature ≥30 degrees
• Previously completed 6-8 CCH injections
• Prior minimal (<20% and/or <10 degrees) responsiveness to CCH administration
• Prior CCH injections must have been performed without use of a Restorex traction device and used the IMPRESS protocol
• Ability to achieve an erection satisfactory for intercourse with or without PDE5 inhibitors
• The patient exhibits a palpable plaque consistent with Peyronie's Disease

You may not qualify if…

• Prior surgical treatment on the penis (other than circumcision)
• Any contraindications to CCH - as determined by the PI
• Inability to complete 8 additional CCH injections
• Severe plaque calcification (i.e. >1 cm shadowing)

Where it is running

• The Male Fertility and Peyronie's Clinic — Orem, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.